Int J Impot Res. 2018;30:262-269.
Hypogonadism therapy and fertility outcomes
Hill ED, Honig SC, Tabb KE, et al.
PreclinicalResearch compound
HMG (Fertility)
Human Menopausal Gonadotropin – 1:1 FSH+LH glycoprotein. Full spermatogenesis induction (dual Leydig + Sertoli axis), IVF superovulation. Clinical Rx for infertility indications (male HypoH + female IVF ovulation induction), NOT doping. Cross-frame: AAS-PCT context covered by the `hmg-perf` entry.
Available at
The links above are labelled third-party affiliate links. MolekulaX does not sell and does not verify product quality.
WHAT IS HMG (FERTILITY)?
Detailed overview
HMG (Human Menopausal Gonadotropin) is a glycoprotein mixture purified from postmenopausal female urine, containing **approximately 75 IU FSH (follicle-stimulating hormone) + 75 IU LH (luteinizing hormone) in 1:1 ratio** per standard ampoule. Modern clinical HMG sources: (1) **urinary-extracted** (Menopur Ferring 2002 EMA, 2005 FDA – higher-purity urinary-purified product; the older Pergonal Serono 1962 was globally withdrawn ~2005 due to vCJD risk mitigation); (2) **recombinant menotropin** (research stage, limited clinical distribution). **Dual gonadotropin-axis stimulus mechanism**: HMG's unique value in clinical fertility treatment is that it stimulates BOTH Leydig cells (LH component → testosterone production) AND Sertoli cells (FSH component → spermatogenesis support + inhibin-B production). HCG monotherapy ONLY activates the Leydig-LH axis (intratesticular testosterone rises, but Sertoli-FSH support is absent) → full spermatogenesis induction requires combined HCG + HMG in hypogonadotropic hypogonadism (HypoH). **Clinical indications** (FDA + EMA Rx): (1) **male spermatogenesis induction** in HypoH (Kallmann syndrome, idiopathic HypoH, pituitary-origin infertility): 75-150 IU SC 3x/week × 6-24 months, stacked with HCG; (2) **female IVF superovulation** and COS (controlled ovarian stimulation): 75-300 IU/day individualized. **Cross-frame note**: same Menopur vial as in AAS-user PCT protocols (`hmg-perf` entry) – different narrative (clinical infertility vs sport-cycle recovery), IDENTICAL pharmacology. WADA-banned year-round (S2 Peptide Hormones).
Mechanism
1:1 FSH+LH glycoprotein mixture – Sertoli-FSHR + Leydig-LHCGR receptor double-stimulus, full HPG axis induction
Dosing (male HypoH spermatogenesis)
75-150 IU SC 3x/week × 6-24 months (stacked with HCG)
Dosing (female IVF/COS)
75-300 IU/day (individualized follicle-monitoring-based titration)
Half-life
FSH component ~12-20 h / LH component ~8-12 h
Legal status
FDA + EMA Rx Menopur (Ferring), WADA S2 (banned in+out-of-competition)
Growth hormone release
The peptide acts on pituitary GHRH or GHS receptors, producing a **physiological, pulsatile GH release**, unlike synthetic rHGH, which keeps levels flat and leads to desensitization. IGF-1 rises into the upper-normal range, driving recovery, muscle protein synthesis, lipolysis and skin quality. Deep-sleep phases lengthen; collagen and bone-matrix synthesis activate. The effect is reversible and does not suppress the endogenous GH axis.
Data console
Lab data
/lab/molecular-data.jsonLIVE
> Classification-
> StructureN/A
> Molecular weightN/A
> Target area-
> Storage2–8°C
> Stability~30 days reconstituted
Research indications
Investigated uses and mechanisms
Growth FactorsFertility / HPTA Support
Growth hormone release
Mimics physiological pulsatile GH secretion; IGF-1 rise.
Recovery & body comp
Muscle mass gain, fat reduction, post-workout recovery.
Sleep quality
Deep-sleep (N3) phases lengthen.
Quality indicators
How to recognize a pure peptide
Purity markers
3Clear oil
Clear or slightly yellow (MCT/sesame/castor oil), particle-free.
Vial integrity
Glass intact, rubber stopper undamaged, aluminum crimp tight.
Label + COA
Manufacturer + LOT + expiry legible; independent HPLC analysis on active content.
Use caution
1BA/BB carrier blend
Excessive benzyl alcohol (>3%) raises PIP risk; verify with UGL manufacturers.
Do not use
2Cloudiness / sediment
Floating particles, cloudiness, or sediment = HARD NO.
Damaged glass / stopper
Cracked vial or loose stopper, sterility compromised.
Interactions & stacks
What to combine and what to avoid
HCG (fertilitás)
SynergisticLH-receptor agonist glycoprotein: fertility induction and HPTA recovery
CJC-1295
SynergisticGHRH analog: sustained growth hormone stimulation
Ipamorelin
SynergisticGHRH + GHRP, classic pulsatile GH stack.
Vitamin C / Zinc / B-complex
SynergisticSupports collagen synthesis and antioxidant capacity.
Caffeine
Requires timingCompatible with morning dosing; avoid late-day stacking.
Insulin
Use cautionContinuous glucose monitoring required.
NSAIDs (Ibuprofen, ASA)
Use cautionLong-term concurrent use may blunt regenerative effects.
Alcohol
AvoidReduces recovery and increases side-effect risk.
Safety
Side effects, stop signs, contraindications
Side effects · 6
- Water retention, mild edema
- Wrist / joint stiffness (carpal-tunnel-like)
- Transient blood-glucose increase
- Mild prolactin / cortisol increase (some peptides)
- PIP (post-injection pain) – especially propionate, trenbolone-ace, or high-BA blends
- Injection-site reaction: lumps, redness, warmth, tenderness
Contraindications · 5
- Pregnancy and breastfeeding
- Active malignancy
- Known allergy to the peptide or its components
- Severe hepatic or renal impairment (medical consultation required)
- Age under 18
Related Peptides
Same therapeutic category
Studies
Related research and clinical findings
J Clin Endocrinol Metab. 2009;94(3):801-808.
Induction of spermatogenesis and fertility during gonadotropin treatment of gonadotropin-deficient infertile men: predictors of fertility outcome
Liu PY, Baker HW, Jayadev V, Zacharin M, Conway AJ, Handelsman DJ.
PMID: 19066302Open
Hum Reprod. 2002;17(3):625-633.
Predicting pregnancy and spermatogenesis by survival analysis during gonadotrophin treatment of gonadotrophin-deficient infertile men
Liu PY, Gebski VJ, Turner L, Conway AJ, Wishart SM, Handelsman DJ.
PMID: 11870114Open
Telegram
Have a question about HMG (Fertility)?
Reach out to an advisor on Telegram. We can help you find the right peptide.
MolekulaX Editorial Team·Source-verified · PubMed · FDA · EMA
Updated: June 2, 2026
The information here is strictly for educational and scientific purposes. It does not replace medical advice or clinical consultation, and it does not encourage illegal substance or pharmaceutical use. Data is sourced. When in doubt, consult your doctor.